Daniel Stauder
Stock Analyst at Citizens Capital Markets
(1.45)
# 3,110
Out of 4,814 analysts
15
Total ratings
14.29%
Success rate
-4.16%
Average return
Main Sectors:
Stocks Rated by Daniel Stauder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRC AtriCure | Reiterates: Market Outperform | $60 | $31.65 | +89.57% | 5 | Apr 2, 2025 | |
| STIM Neuronetics | Maintains: Market Outperform | $3 → $7 | $3.77 | +85.68% | 1 | Mar 5, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Buy | $105 → $110 | $86.28 | +27.49% | 4 | Feb 28, 2025 | |
| AXON Axon Enterprise | Reiterates: Market Outperform | $725 | $559.53 | +29.57% | 1 | Feb 26, 2025 | |
| AORT Artivion | Reiterates: Market Outperform | $33 | $22.93 | +43.95% | 3 | Feb 25, 2025 | |
| AVNS Avanos Medical | Reiterates: Market Perform | n/a | $12.40 | - | 1 | May 7, 2024 |
AtriCure
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $31.65
Upside: +89.57%
Neuronetics
Mar 5, 2025
Maintains: Market Outperform
Price Target: $3 → $7
Current: $3.77
Upside: +85.68%
LeMaitre Vascular
Feb 28, 2025
Maintains: Buy
Price Target: $105 → $110
Current: $86.28
Upside: +27.49%
Axon Enterprise
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $725
Current: $559.53
Upside: +29.57%
Artivion
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $22.93
Upside: +43.95%
Avanos Medical
May 7, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $12.40
Upside: -